5-chloro-2-methyl-3-phenyl-3H-quinazolin-4-one | 3359-99-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5-chloro-2-methyl-3-phenyl-3H-quinazolin-4-one
• 英文别名: 5-chloro-2-methyl-3-phenylquinazolin-4(3H)-one；4(3h)-Quinazolinone,5-chloro-2-methyl-3-phenyl-；5-chloro-2-methyl-3-phenylquinazolin-4-one
• CAS: 3359-99-7
• 化学式: C₁₅H₁₁ClN₂O
• 分子量: 270.718
• InChiKey: BHJFOIVDGPKWBX-UHFFFAOYSA-N

物化性质

• 熔点：
  141-142 °C
• 沸点：
  435.2±47.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-chloro-2-methyl-3-phenyl-3H-quinazolin-4-one 在 tris-(dibenzylideneacetone)dipalladium(0) 、 三叔丁基膦 、 N-甲基二环己基胺 、 盐酸羟胺 、 potassium hydroxide 作用下， 以 甲醇 、 正己烷 、 甲苯 为溶剂， 反应 55.0h， 生成 N-hydroxy-3-(2-methyl-4-oxo-3-phenyl-3,4-dihydro-quinazolin-5-yl)acrylamide
  参考文献：
  名称：

  Quinazolin-4-one Derivatives as Selective Histone Deacetylase-6 Inhibitors for the Treatment of Alzheimer’s Disease

  摘要：

  Novel quinazolin-4-one derivatives containing a hydroxamic acid moiety were designed and synthesized. All compounds were subjected to histone deacetylase (HDAC) enzymatic assays to identify selective HDAC6 inhibitors with nanomolar IC50 values. (E)-3-(2-Ethyl-7-fluoro-4-oxo-3-phenethyl-3,4-dihydroquinazolin-6-yl)-N-hydroxyacrylamide, 4h, NHis the most potent HDAC6 inhibitor (IC50, 8 nM). In vitro, these compounds induced neurite outgrowth accompanied by growth-associated protein 43 expression, and they enhanced the synaptic activities of PC12 and SH-SY5Y neuronal cells without producing toxic or mitogenic effects. Several of the compounds dramatically increased nonhistone protein acetylation, specifically of g-tubulin. Some of the more potent HDAC6 inhibitors decreased zinc-mediated beta-amyloid aggregation in vitro. N-Hydroxy-3-(2-methyl-4-oxo-3-phenethyl-3,4-dihydroquinazolin-7-yl)-acrylarnide, 3f, the most promising drug candidate, selectively inhibits HDAC6 (IC50,29 nM), practically does not affect human ether-a-go-go-related membrane channel activity (IC50 >10 mu M) or cytochrome P450 activity (IC50 >63 mu M) in vitro, and significantly improves learning-based performances of mice with beta-amyloid-induced hippocampal lesions.

  DOI：

  10.1021/jm400564j
• 作为产物：
  描述：

  2-acetamido-N-phenylbenzamide 在 哌啶 、 silica gel 作用下， 以 乙酸乙酯 为溶剂， 反应 60.0h， 以64%的产率得到5-chloro-2-methyl-3-phenyl-3H-quinazolin-4-one
  参考文献：
  名称：

  Quinazolin-4-one Derivatives as Selective Histone Deacetylase-6 Inhibitors for the Treatment of Alzheimer’s Disease

  摘要：

  Novel quinazolin-4-one derivatives containing a hydroxamic acid moiety were designed and synthesized. All compounds were subjected to histone deacetylase (HDAC) enzymatic assays to identify selective HDAC6 inhibitors with nanomolar IC50 values. (E)-3-(2-Ethyl-7-fluoro-4-oxo-3-phenethyl-3,4-dihydroquinazolin-6-yl)-N-hydroxyacrylamide, 4h, NHis the most potent HDAC6 inhibitor (IC50, 8 nM). In vitro, these compounds induced neurite outgrowth accompanied by growth-associated protein 43 expression, and they enhanced the synaptic activities of PC12 and SH-SY5Y neuronal cells without producing toxic or mitogenic effects. Several of the compounds dramatically increased nonhistone protein acetylation, specifically of g-tubulin. Some of the more potent HDAC6 inhibitors decreased zinc-mediated beta-amyloid aggregation in vitro. N-Hydroxy-3-(2-methyl-4-oxo-3-phenethyl-3,4-dihydroquinazolin-7-yl)-acrylarnide, 3f, the most promising drug candidate, selectively inhibits HDAC6 (IC50,29 nM), practically does not affect human ether-a-go-go-related membrane channel activity (IC50 >10 mu M) or cytochrome P450 activity (IC50 >63 mu M) in vitro, and significantly improves learning-based performances of mice with beta-amyloid-induced hippocampal lesions.

  DOI：

  10.1021/jm400564j

文献信息

• [EN] INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND HISTONE DEACETYLASE FOR TREATMENT OF CANCER<br/>[FR] INHIBITEURS DE LA PHOSPHOINOSITIDE 3-KINASE ET DE L'HISTONE DÉSACÉTYLASE POUR LE TRAITEMENT DU CANCER
  申请人：US HEALTH

  公开号：WO2018237007A1

  公开（公告）日：2018-12-27

  The present invention is directed to a dual inhibitor of phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC), including a core containing a quinazoline moiety or a quinazolin-4(3H)-one moiety, a kinase hinge binding moiety, and a histone deacetylase pharmacophore, a pharmaceutically acceptable salt thereof, a prodrug thereof, or solvate thereof. The present invention is also directed to a histone deacetylase inhibitor, including a core containing a quinazolin-4(3H)-one moiety and a histone deacetylase pharmacophore.

  本发明涉及一种磷脂酰肌醇3-激酶（PI3K）和组蛋白去乙酰化酶（HDAC）的双重抑制剂，包括一个含有喹唑啉基团或喹唑啉-4(3H)-酮基团的核心，一个激酶铰链结合基团，和一个组蛋白去乙酰化酶药效团，以及其药用盐、前药或溶剂化物。本发明还涉及一种组蛋白去乙酰化酶抑制剂，包括一个含有喹唑啉-4(3H)-酮基团和一个组蛋白去乙酰化酶药效团的核心。
• HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：Korea Research Institute of Chemical Technology

  公开号：EP3312175A1

  公开（公告）日：2018-04-25

  The present invention relates to a heteroaryl derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition for preventing or treating diseases associated with PI3 kinases, containing the same as an active ingredient. The heteroaryl derivative according to the present invention has an excellent effect of selectively inhibiting PI3 kinases, thereby being useful in preventing or treating PI3 kinase diseases such as: cancers such as hematologic malignancy, ovarian cancer, uterine cervical cancer, breast cancer, colorectal cancer, liver cancer, gastric cancer, pancreatic cancer, colon cancer, peritoneal metastatic cancer, skin cancer, bladder cancer, prostate cancer, lung cancer, osteosarcoma, fibrous tumors, and brain tumors; autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosis, multiple sclerosis, diabetes mellitus, hyperthyroidism, myasthenia, Crohn's disease, ankylosing spondylitis, autoimmune pernicious anemia, and Sjogren's syndrome; and respiratory diseases such as chronic obstructive pulmonary disease (COPD), rhinitis, asthma, chronic bronchitis, chronic pulmonary inflammatory diseases, silicosis, pulmonary sarcoidosis, pleurisy, alveolitis, angitis, pneumatosis, pneumonia, and bronchiectasis.

  本发明涉及一种杂芳基衍生物或其药学上可接受的盐、其制备方法以及一种用于预防或治疗与PI3激酶相关疾病的药物组合物，其中含有杂芳基衍生物或其药学上可接受的盐、其制备方法以及一种用于预防或治疗与PI3激酶相关疾病的药物组合物，其中含有杂芳基衍生物或其药学上可接受的盐作为活性成分。根据本发明的杂芳基衍生物具有很好的选择性抑制 PI3 激酶的效果，因此可用于预防或治疗 PI3 激酶疾病，如癌症，如血液系统恶性肿瘤、卵巢癌、子宫颈癌、乳腺癌、结直肠癌、肝癌、胃癌、胰腺癌、结肠癌、腹膜转移癌、皮肤癌、膀胱癌、前列腺癌、肺癌、骨肉瘤、纤维瘤和脑瘤；自身免疫性疾病，如类风湿性关节炎、系统性红斑狼疮、多发性硬化症、糖尿病、甲状腺机能亢进症、肌无力、克罗恩病、强直性脊柱炎、自身免疫性恶性贫血和 Sjogren 综合征；呼吸系统疾病，如慢性阻塞性肺病（COPD）、鼻炎、哮喘、慢性支气管炎、慢性肺部炎症、矽肺、肺肉瘤病、胸膜炎、肺泡炎、血管炎、肺气肿、肺炎和支气管扩张。
• SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AS PI3-KINASE INHIBITORS
  申请人：Calitor Sciences, LLC

  公开号：EP3046563B1

  公开（公告）日：2019-05-29
• INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND HISTONE DEACETYLASE FOR TREATMENT OF CANCER
  申请人：THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC

  公开号：US20200165257A1

  公开（公告）日：2020-05-28

  The present invention is directed to a dual inhibitor of phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC), including a core containing a quinazoline moiety or a quinazolin-4(3H)-one moiety, a kinase hinge binding moiety, and a histone deacetylase pharmacophore, a pharmaceutically acceptable salt thereof, a prodrug thereof, or solvate thereof. The present invention is also directed to a histone deacetylase inhibitor, including a core containing a quinazolin-4(3H)-one moiety and a histone deacetylase pharmacophore.
• US9670194B2
  申请人：——

  公开号：US9670194B2

  公开（公告）日：2017-06-06